Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for Journal of Ophthalmology, enter your email address in the box below.

Journal of Ophthalmology
Volume 2015, Article ID 275435, 10 pages
http://dx.doi.org/10.1155/2015/275435
Review Article

Role of Peroxisome Proliferator-Activated Receptor γ in Ocular Diseases

Su Zhang, Hongwei Gu, and Nan Hu

Department of Ophthalmology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China

Received 27 February 2015; Accepted 19 May 2015

Academic Editor: Enrico Peiretti

Copyright © 2015 Su Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Tontonoz and B. M. Spiegelman, “Fat and beyond: the diverse biology of PPARγ,” Annual Review of Biochemistry, vol. 77, pp. 289–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli, “Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors,” Cell, vol. 68, no. 5, pp. 879–887, 1992. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Chen, S. W. Law, and B. W. O'Malley, “Identification of two mPPAR related receptors and evidence for the existence of five subfamily members,” Biochemical and Biophysical Research Communications, vol. 196, no. 2, pp. 671–677, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Zhu, K. Alvares, Q. Huang, M. S. Rao, and J. K. Reddy, “Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver,” The Journal of Biological Chemistry, vol. 268, no. 36, pp. 26817–26820, 1993. View at Google Scholar · View at Scopus
  5. Y. Barak, M. C. Nelson, E. S. Ong et al., “PPARγ is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. X. Xin, S. Yang, J. Kowalski, and M. E. Gerritsen, “Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo,” Journal of Biological Chemistry, vol. 274, no. 13, pp. 9116–9121, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. J. V. Jester and D. J. Brown, “Wakayama symposium: peroxisome proliferator-activated receptor-gamma (PPARgamma) and meibomian gland dysfunction,” Ocular Surface, vol. 10, no. 4, pp. 224–229, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. K. Song, B. D. Roufogalis, and T. H. W. Huang, “Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR-γ-related pharmacology,” British Journal of Pharmacology, vol. 165, no. 1, pp. 4–19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. L. L. C. Poulsen, M. Siersbaek, and S. Mandrup, “PPARs: fatty acid sensors controlling metabolism,” Seminars in Cell and Developmental Biology, vol. 23, no. 6, pp. 631–639, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Abdelrahman, A. Sivarajah, and C. Thiemermann, “Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock,” Cardiovascular Research, vol. 65, no. 4, pp. 772–781, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. S. van Neerven and J. Mey, “RAR/RXR and PPAR/RXR signaling in spinal cord injury,” PPAR Research, vol. 2007, Article ID 29275, 14 pages, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. R. T. Nolte, G. B. Wisely, S. Westin et al., “Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-gamma,” Nature, vol. 395, no. 6698, pp. 137–143, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Cariou, B. Charbonnel, and B. Staels, “Thiazolidinediones and PPARγ agonists: time for a reassessment,” Trends in Endocrinology and Metabolism, vol. 23, no. 5, pp. 205–215, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Kung and R. R. Henry, “Thiazolidinedione safety,” Expert Opinion on Drug Safety, vol. 11, no. 4, pp. 565–579, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. J. M. Olefsky and A. R. Saltiel, “PPARγ and the treatment of insulin resistance,” Trends in Endocrinology and Metabolism, vol. 11, no. 9, pp. 362–368, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. R. F. Kletzien, S. D. Clarke, and R. G. Ulrich, “Enhancement of adipocyte differentiation by an insulin-sensitizing agent,” Molecular Pharmacology, vol. 41, no. 2, pp. 393–398, 1992. View at Google Scholar · View at Scopus
  17. E. D. Rosen and B. M. Spiegelman, “PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth,” The Journal of Biological Chemistry, vol. 276, no. 41, pp. 37731–37734, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Tontonoz, E. Hu, R. A. Graves, A. I. Budavari, and B. M. Spiegelman, “mPPARgamma2: tissue-specific regulator of an adipocyte enhancer,” Genes and Development, vol. 8, no. 10, pp. 1224–1234, 1994. View at Publisher · View at Google Scholar · View at Scopus
  19. A. W. Musser, “The planning, operation, and function of a clinical laboratory in a teaching hospital,” CRC Critical Reviews in Clinical Laboratory Sciences, vol. 6, no. 1, pp. 47–66, 1975. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Lemberger, B. Desvergne, and W. Wahli, “Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology,” Annual Review of Cell and Developmental Biology, vol. 12, pp. 335–363, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Panigrahy, S. Huang, M. W. Kieran, and A. Kaipainen, “PPARγ as a therapeutic target for tumor angiogenesis and metastasis,” Cancer Biology and Therapy, vol. 4, no. 7, pp. 687–693, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Bishop-Bailey, “PPARs and angiogenesis,” Biochemical Society Transactions, vol. 39, no. 6, pp. 1601–1605, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. P. J. Sime, “The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis,” Journal of Investigative Medicine, vol. 56, no. 2, pp. 534–538, 2008. View at Google Scholar · View at Scopus
  24. C. Giaginis, A. Giagini, and S. Theocharis, “Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis,” Pharmacological Research, vol. 60, no. 3, pp. 160–169, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Polvani, M. Tarocchi, and A. Galli, “PPAR and oxidative stress: con(β) catenating NRF2 and FOXO,” PPAR Research, vol. 2012, Article ID 641087, 15 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Bishop-Bailey and J. Bystrom, “Emerging roles of peroxisome proliferator-activated receptor-β/δ in inflammation,” Pharmacology and Therapeutics, vol. 124, no. 2, pp. 141–150, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. R. B. Clark, “The role of PPARs in inflammation and immunity,” Journal of Leukocyte Biology, vol. 71, no. 3, pp. 388–400, 2002. View at Google Scholar · View at Scopus
  28. X. Zhang and H. A. Young, “PPAR and immune system—what do we know?” International Immunopharmacology, vol. 2, no. 8, pp. 1029–1044, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Szatmari, E. Rajnavolgyi, and L. Nagy, “PPARγ, a lipid-activated transcription factor as a regulator of dendritic cell function,” Annals of the New York Academy of Sciences, vol. 1088, pp. 207–218, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Sokolowska, M. L. Kowalski, and R. Pawliczak, “Peroxisome proliferator-activated receptors-gamma (PPAR-gamma) and their role in immunoregulation and inflammation control,” Postępy Higieny i Medycyny Doświadczalnej, vol. 59, pp. 472–484, 2005. View at Google Scholar
  31. L. Szeles, D. Torocsik, and L. Nagy, “PPARgamma in immunity and inflammation: cell types and diseases,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1014–1030, 2007. View at Google Scholar
  32. M. Colucciello, “Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus,” Archives of Ophthalmology, vol. 123, no. 9, pp. 1273–1275, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. D. S. Fong and R. Contreras, “Glitazone use associated with diabetic macular edema,” The American Journal of Ophthalmology, vol. 147, no. 4, pp. 583.e1–586.e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. N. V. Niemeyer and L. M. Janney, “Thiazolidinedione-induced edema,” Pharmacotherapy, vol. 22, no. 7, pp. 924–929, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. I. Idris, G. Warren, and R. Donnelly, “Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes,” Archives of Internal Medicine, vol. 172, no. 13, pp. 1005–1011, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Baba, K. Shimada, S. Neugebauer, D. Yamada, S. Hashimoto, and T. Watanabe, “The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients,” Diabetes Care, vol. 24, no. 5, pp. 953–954, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Emoto, T. Anno, Y. Sato et al., “Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes,” Diabetes, vol. 50, no. 5, pp. 1166–1170, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. D. T. Azar, “Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis),” Transactions of the American Ophthalmological Society, vol. 104, pp. 264–302, 2006. View at Google Scholar · View at Scopus
  39. C. Giaginis, A. Margeli, and S. Theocharis, “Peroxisome proliferator-activated receptor-γ ligands as investigational modulators of angiogenesis,” Expert Opinion on Investigational Drugs, vol. 16, no. 10, pp. 1561–1572, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Margeli, G. Kouraklis, and S. Theocharis, “Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis,” Angiogenesis, vol. 6, no. 3, pp. 165–169, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Usui, K. Sugisaki, A. Iriyama et al., “Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor,” Investigative Ophthalmology and Visual Science, vol. 49, no. 10, pp. 4370–4376, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Uchiyama, A. Shimizu, Y. Masuda, S. Nagasaka, Y. Fukuda, and H. Takahashi, “An ophthalmic solution of a peroxisome proliferator-activated receptor gamma agonist prevents corneal inflammation in a rat alkali burn model,” Molecular Vision, vol. 19, pp. 2135–2150, 2013. View at Google Scholar · View at Scopus
  43. M. A. Sarayba, L. Li, T. Tungsiripat et al., “Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-γ ligand,” Experimental Eye Research, vol. 80, no. 3, pp. 435–442, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Risau, “Mechanisms of angiogenesis,” Nature, vol. 386, no. 6626, pp. 671–674, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. N. Wang, L. Verna, N. G. Chen et al., “Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells,” The Journal of Biological Chemistry, vol. 277, no. 37, pp. 34176–34181, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. K. R. Huxlin, H. B. Hindman, K.-I. Jeon et al., “Topical rosiglitazone is an effective anti-scarring agent in the cornea,” PLoS ONE, vol. 8, no. 8, Article ID e70785, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. A. E. Kuriyan, G. M. Lehmann, A. A. Kulkarni et al., “Electrophilic PPARγ ligands inhibit corneal fibroblast to myofibroblast differentiation in vitro: a potentially novel therapy for corneal scarring,” Experimental Eye Research, vol. 94, no. 1, pp. 136–145, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Pan, J. Chen, J. Xu, M. Chen, and R. Ma, “Antifibrotic effect by activation of peroxisome proliferator-activated receptor-gamma in corneal fibroblasts,” Molecular Vision, vol. 15, pp. 2279–2286, 2009. View at Google Scholar · View at Scopus
  49. H.-W. Pan, J.-T. Xu, and J.-S. Chen, “Pioglitazone inhibits TGFbeta induced keratocyte transformation to myofibroblast and extracellular matrix production,” Molecular Biology Reports, vol. 38, no. 7, pp. 4501–4508, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Saika, O. Yamanaka, Y. Okada et al., “Effect of overexpression of pparγ on the healing process of corneal alkali burn in mice,” American Journal of Physiology: Cell Physiology, vol. 293, no. 1, pp. C75–C86, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. O. Yamanaka, K.-I. Miyazaki, A. Kitano, S. Saika, Y. Nakajima, and K. Ikeda, “Suppression of injury-induced conjunctiva scarring by peroxisome proliferator-activated receptor γ gene transfer in mice,” Investigative Ophthalmology & Visual Science, vol. 50, no. 1, pp. 187–193, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. F. Fan, Y. Li, X. Duan, T. Zhao, D. Pan, and H. Chen, “Rosiglitazone attenuates activation of human Tenon's fibroblasts induced by transforming growth factor-beta1,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 250, no. 8, pp. 1213–1220, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. X.-X. Yang, J. Chen, Q. Zhou et al., “Troglitazone induced apoptosis of human pterygium fibroblasts through a mitochondrial-dependent pathway,” International Journal of Ophthalmology, vol. 4, no. 2, pp. 143–146, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Hyvonen, A. R. Khomutov, R. M. Khomutov, S. Lapinjoki, and T. O. Eloranta, “Uptake of 3H-labeled 1-aminooxy-3-aminopropane by baby hamster kidney cells,” Journal of Biochemistry, vol. 107, no. 6, pp. 817–820, 1990. View at Google Scholar · View at Scopus
  55. Y. Chen, X. Zhang, L. Yang et al., “Decreased PPAR-γ expression in the conjunctiva and increased expression of TNF-α and IL-1β in the conjunctiva and tear fluid of dry eye mice,” Molecular Medicine Reports, vol. 9, no. 5, pp. 2015–2023, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. C. Beauregard and P. C. Brandt, “Peroxisome proliferator-activated receptor agonists inhibit interleukin-1beta-mediated nitric oxide production in cultured lacrimal gland acinar cells,” Journal of Ocular Pharmacology and Therapeutics, vol. 19, no. 6, pp. 579–587, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. C. J. Nien, S. Massei, G. Lin et al., “Effects of age and dysfunction on human meibomian glands,” Archives of Ophthalmology, vol. 129, no. 4, pp. 462–469, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. C. J. Nien, J. R. Paugh, S. Massei, A. J. Wahlert, W. W. Kao, and J. V. Jester, “Age-related changes in the meibomian gland,” Experimental Eye Research, vol. 89, no. 6, pp. 1021–1027, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. R. J. Herm, “Age-related macular degeneration,” The New England Journal of Medicine, vol. 359, no. 16, pp. 1735–1736, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. A. A. Herzlich, X. Ding, D. Shen, R. J. Ross, J. Tuo, and C. C. Chan, “Peroxisome proliferator-activated receptor expression in murine models and humans with age-related macular degeneration,” The Open Biology Journal, vol. 2, no. 1, pp. 141–148, 2009. View at Publisher · View at Google Scholar
  61. T. Murata, S. He, M. Hangai et al., “Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization,” Investigative Ophthalmology and Visual Science, vol. 41, no. 8, pp. 2309–2317, 2000. View at Google Scholar · View at Scopus
  62. J. P. Vanden Heuvel, “Nutrigenomics and nutrigenetics of ω3 polyunsaturated fatty acids,” Progress in Molecular Biology and Translational Science, vol. 108, pp. 75–112, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. E. W.-T. Chong, A. J. Kreis, T. Y. Wong, J. A. Simpson, and R. H. Guymer, “Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysis,” Archives of Ophthalmology, vol. 126, no. 6, pp. 826–833, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. O. Strauss, The Retinal Pigment Epithelium, 1995.
  65. J. Cai, K. C. Nelson, M. Wu, P. J. Sternberg, and D. P. Jones, “Oxidative damage and protection of the RPE,” Progress in Retinal and Eye Research, vol. 19, no. 2, pp. 205–221, 2000. View at Publisher · View at Google Scholar · View at Scopus
  66. A. V. Ershov and N. G. Bazan, “Photoreceptor phagocytosis selectively activates PPARgamma expression in retinal pigment epithelial cells,” Journal of Neuroscience Research, vol. 60, no. 3, pp. 328–337, 2000. View at Google Scholar · View at Scopus
  67. S. Qin, A. P. McLaughlin, and G. W. de Vries, “Protection of RPE cells from oxidative injury by 15-deoxy-Δ 12,14-prostaglandin J2 by augmenting GSH and activating MAPK,” Investigative Ophthalmology & Visual Science, vol. 47, no. 11, pp. 5098–5105, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. T. K. Garg and J. Y. Chang, “Oxidative stress causes ERK phosphorylation and cell death in cultured retinal pigment epithelium: prevention of cell death by AG126 and 15-deoxy-delta 12, 14-PGJ2,” BMC Ophthalmology, vol. 3, article 5, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. G. A. Rodrigues, F. Maurier-Mahé, D.-L. Shurland et al., “Differential effects of PPARγ ligands on oxidative stress-induced death of retinal pigmented epithelial cells,” Investigative Ophthalmology and Visual Science, vol. 52, no. 2, pp. 890–903, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. R. Walczak and P. Tontonoz, “PPARadigms and PPARadoxes: expanding roles for PPARγ in the control of lipid metabolism,” Journal of Lipid Research, vol. 43, no. 2, pp. 177–186, 2002. View at Google Scholar · View at Scopus
  71. C. H. Lee and R. M. Evans, “Peroxisome proliferator-activated receptor-gamma in macrophage lipid homeostasis,” Trends in Endocrinology and Metabolism, vol. 13, no. 8, pp. 331–335, 2002. View at Publisher · View at Google Scholar · View at Scopus
  72. P. Delerive, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors in inflammation control,” Journal of Endocrinology, vol. 169, no. 3, pp. 453–459, 2001. View at Publisher · View at Google Scholar · View at Scopus
  73. A. C. Calkin, J. M. Forbes, C. M. Smith et al., “Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1903–1909, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Ji, G. Kronenberg, M. Balkaya et al., “Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome,” Experimental Neurology, vol. 216, no. 2, pp. 321–328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Ren, C. Sun, Y. Sun et al., “PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation,” Vascular Pharmacology, vol. 51, no. 2-3, pp. 169–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. J. Kim, Y.-S. Oh, and S.-H. Shinn, “Troglitazone reverses the inhibition of nitric oxide production by high glucose in cultured bovine retinal pericytes,” Experimental Eye Research, vol. 81, no. 1, pp. 65–70, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. K. Muranaka, Y. Yanagi, Y. Tamaki et al., “Effects of peroxisome proliferator-activated receptor γ and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model,” Investigative Ophthalmology and Visual Science, vol. 47, no. 10, pp. 4547–4552, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. Z. Zheng, H. Chen, H. Wang et al., “Improvement of retinal vascular injury in diabetic rats by statins is associated with the inhibition of mitochondrial reactive oxygen species pathway mediated by peroxisome proliferator-activated receptor γ coactivator 1α,” Diabetes, vol. 59, no. 9, pp. 2315–2325, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Higuchi, K. Ohashi, R. Shibata, S. Sono-Romanelli, K. Walsh, and N. Ouchi, “Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 1, pp. 46–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. H. Hatanaka, N. Koizumi, N. Okumura et al., “Epithelial-mesenchymal transition-like phenotypic changes of retinal pigment epithelium induced by TGF-γ Are prevented by PPAR-γ agonists,” Investigative Ophthalmology & Visual Science, vol. 53, no. 11, pp. 6955–6963, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. P. Li, X. Xu, Z. Zheng, B. Zhu, Y. Shi, and K. Liu, “Protective effects of rosiglitazone on retinal neuronal damage in diabetic rats,” Current Eye Research, vol. 36, no. 7, pp. 673–679, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. Y. Jiang, S. Thakran, R. Bheemreddy et al., “Pioglitazone normalizes insulin signaling in the diabetic rat retina through reduction in tumor necrosis factor alpha and suppressor of cytokine signaling 3,” The Journal of Biological Chemistry, vol. 289, no. 38, pp. 26395–26405, 2014. View at Publisher · View at Google Scholar
  83. T. Murata, Y. Hata, T. Ishibashi et al., “Response of experimental retinal neovascularization to thiazolidinediones,” Archives of Ophthalmology, vol. 119, no. 5, pp. 709–717, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. L. Q. Shen, A. Child, G. M. Weber, J. Folkman, and L. P. Aiello, “Rosiglitazone and delayed onset of proliferative diabetic retinopathy,” Archives of Ophthalmology, vol. 126, no. 6, pp. 793–799, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Azar, G. M. El-Mollayess, L. Al Shaar, H. I. Salti, and Z. F. Bashshur, “Impact of thiazolidinediones on macular thickness and volume in diabetic eyes,” Canadian Journal of Ophthalmology, vol. 48, no. 4, pp. 312–316, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. A. K. Tarbett, R. C. VanRoekel, R. S. Howard, and R. A. Vigersky, “The use of optical coherence tomography to determine the effect of thiazolidinediones on retinal thickness in patients with type 2 diabetes,” Journal of Diabetes Science and Technology, vol. 5, no. 4, pp. 945–951, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Asgary, G. A. Naderi, N. Sarraf-Zadegan, and R. Vakili, “The inhibitory effects of pure flavonoids on in vitro protein glycosylation,” Journal of Herbal Pharmacotherapy, vol. 2, no. 2, pp. 47–55, 2002. View at Publisher · View at Google Scholar · View at Scopus
  88. H. Y. Wang and M. L. Cheng, “Effects of Dan-shao-hua-xian on expression of PPAR-gamma and NF-kappa B in rat liver fibrosis,” Hepatobiliary and Pancreatic Diseases International, vol. 7, no. 2, pp. 179–184, 2008. View at Google Scholar · View at Scopus
  89. K. Motomura, Y. Fujiwara, N. Kiyota et al., “Astragalosides isolated from the root of astragalus radix inhibit the formation of advanced glycation end products,” Journal of Agricultural and Food Chemistry, vol. 57, no. 17, pp. 7666–7672, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. X.-C. Liang, N. Hagino, S.-S. Guo, T. Tsutsumi, and S. Kobayashi, “Therapeutic efficacy of Stephania tetrandra S. Moore for treatment of neovascularization of retinal capillary (retinopathy) in diabetes—in vitro study,” Phytomedicine, vol. 9, no. 5, pp. 377–384, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Zhou, S. Zheng, J. Lin, Q.-J. Zhang, and A. Chen, “The interruption of the PDGF and EGF signaling pathways by curcumin stimulates gene expression of PPARγ in rat activated hepatic stellate cell in vitro,” Laboratory Investigation, vol. 87, no. 5, pp. 488–498, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. R. A. Kowluru and M. Kanwar, “Effects of curcumin on retinal oxidative stress and inflammation in diabetes,” Nutrition and Metabolism, vol. 4, article 8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. T. Mrudula, P. Suryanarayana, P. N. B. S. Srinivas, and G. B. Reddy, “Effect of curcumin on hyperglycemia-induced vascular endothelial growth factor expression in streptozotocin-induced diabetic rat retina,” Biochemical and Biophysical Research Communications, vol. 361, no. 2, pp. 528–532, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Balasubramanyam, A. A. Koteswari, R. S. Kumar, S. F. Monickaraj, J. U. Maheswari, and V. Mohan, “Curcumin-induced inhibition of cellular reactive oxygen species generation: novel therapeutic implications,” Journal of Biosciences, vol. 28, no. 6, pp. 715–721, 2003. View at Publisher · View at Google Scholar · View at Scopus
  95. J.-L. Liu, J.-W. Jin, S.-J. Pei, and C. Wang, “Flurbiprofen axetil promotes neuroprotection by activation of cerebral peroxisome proliferator-activated receptor gamma after focal cerebral ischemia in rats,” Chinese Medical Journal, vol. 125, no. 20, pp. 3719–3724, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. A. R. Carta, L. Frau, A. Pisanu, J. Wardas, S. Spiga, and E. Carboni, “Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model,” Neuroscience, vol. 194, pp. 250–261, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. L. Escribano, A.-M. Simón, A. Pérez-Mediavilla, P. Salazar-Colocho, J. D. Río, and D. Frechilla, “Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model,” Biochemical and Biophysical Research Communications, vol. 379, no. 2, pp. 406–410, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Kiaei, K. Kipiani, J. Chen, N. Y. Calingasan, and M. F. Beal, “Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis,” Experimental Neurology, vol. 191, no. 2, pp. 331–336, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. E. Esposito and S. Cuzzocrea, “Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury,” Expert Opinion on Therapeutic Targets, vol. 15, no. 8, pp. 943–959, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. L. Qi, A. Jacob, P. Wang, and R. Wu, “Peroxisome proliferator activated receptor-gamma and traumatic brain injury,” International Journal of Clinical and Experimental Medicine, vol. 3, no. 4, pp. 283–292, 2010. View at Google Scholar · View at Scopus
  101. C. H. Lee, O. K. Park, K.-Y. Yoo et al., “The role of peroxisome proliferator-activated receptor γ, and effects of its agonist, rosiglitazone, on transient cerebral ischemic damage,” Journal of the Neurological Sciences, vol. 300, no. 1-2, pp. 120–129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. Y. Zhao, A. Patzer, T. Herdegen, P. Gohlke, and J. Culman, “Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats,” The FASEB Journal, vol. 20, no. 8, pp. 1162–1175, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. J.-H. Yi, S.-W. Park, N. Brooks, B. T. Lang, and R. Vemuganti, “PPARγ agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms,” Brain Research, vol. 1244, pp. 164–172, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. J. Zhu, J. Zhang, M. Ji et al., “The role of peroxisome proliferator-activated receptor and effects of its agonist, pioglitazone, on a rat model of optic nerve crush: PPARgamma in retinal neuroprotection,” PLoS ONE, vol. 8, no. 7, Article ID e68935, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. X.-Y. Zhang, Y.-Q. Xiao, Y. Zhang, and W. Ye, “Protective effect of pioglitazone on retinal ischemia/ reperfusion injury in rats,” Investigative Ophthalmology and Visual Science, vol. 54, no. 6, pp. 3912–3921, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. L. Y. Mimura, S. M. F. Villares, M. L. R. Monteiro, I. C. Guazzelli, and W. Bloise, “Peroxisome proliferator-activated receptor-γ gene expression in orbital adipose/connective tissues is increased during the active stage of Graves' ophthalmopathy,” Thyroid, vol. 13, no. 9, pp. 845–850, 2003. View at Publisher · View at Google Scholar · View at Scopus
  107. S. Kumar, M. J. Coenen, P. E. Scherer, and R. S. Bahn, “Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 2, pp. 930–935, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. G. M. Lehmann, T. M. Garcia-Bates, T. J. Smith, S. E. Feldon, and R. P. Phipps, “Regulation of lymphocyte function by PPARgamma: relevance to thyroid eye disease-related inflammation,” PPAR Research, vol. 2008, Article ID 895901, 12 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. P. Zhao, Y. Deng, P. Gu et al., “Insulin-like growth factor 1 promotes the proliferation and adipogenesis of orbital adipose-derived stromal cells in thyroid-associated ophthalmopathy,” Experimental Eye Research, vol. 107, pp. 65–73, 2013. View at Publisher · View at Google Scholar · View at Scopus
  110. K. Starkey, A. Heufelder, G. Baker et al., “Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use?” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 1, pp. 55–59, 2003. View at Publisher · View at Google Scholar · View at Scopus
  111. W. Bloise, L. Y. Mimura, J. Moura, and W. Nicolau, “Treatment of mild to moderate graves' ophthalmopathy with sodium diclofenac: a pilot study,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 55, no. 9, pp. 692–695, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. N. Guo, C. F. Woeller, S. E. Feldon, and R. P. Phipps, “Peroxisome proliferator-activated receptor γ ligands inhibit transforming growth factor-β-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts,” Journal of Biological Chemistry, vol. 286, no. 21, pp. 18856–18867, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. B. Bhatia, C. R. Potts, C. Guldal et al., “Hedgehog-mediated regulation of PPARgamma controls metabolic patterns in neural precursors and shh-driven medulloblastoma,” Acta Neuropathologica, vol. 123, no. 4, pp. 587–600, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. C. Lee, J. A. Ramirez, J. Guitart, and L. K. Diaz, “Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression,” Journal of Cutaneous Pathology, vol. 35, no. 11, pp. 989–994, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. P. Knapp, A. Chabowski, A. Bachnio-Zabielska, K. Jarzbek, and S. Wołczyski, “Altered peroxisome-proliferator activated receptors expression in human endometrial cancer,” PPAR Research, vol. 2012, Article ID 471524, 5 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. S. Meyer, T. Vogt, M. Landthaler et al., “Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma,” PPAR Research, vol. 2010, Article ID 848645, 11 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. M. C. Herwig, C. Bergstrom, J. R. Wells, T. Höller, and H. E. Grossniklaus, “M2/M1 ratio of tumor associated macrophages and PPAR-gamma expression in uveal melanomas with class 1 and class 2 molecular profiles,” Experimental Eye Research, vol. 107, pp. 52–58, 2013. View at Publisher · View at Google Scholar · View at Scopus
  118. M. K. Racke, A. R. Gocke, M. Muir, A. Diab, P. D. Drew, and A. E. Lovett-Racke, “Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis,” Journal of Nutrition, vol. 136, no. 3, pp. 700–703, 2006. View at Google Scholar · View at Scopus
  119. J. M. Choi and A. L. M. Bothwell, “The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases,” Molecules and Cells, vol. 33, no. 3, pp. 217–222, 2012. View at Publisher · View at Google Scholar · View at Scopus
  120. H. Ramkalawan, Y.-Z. Wang, A. Hurbungs et al., “Pioglitazone, PPARγ agonist, attenuates experimental autoimmune neuritis,” Inflammation, vol. 35, no. 4, pp. 1338–1347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. Y. Okunuki, Y. Usui, H. Nakagawa et al., “Peroxisome proliferator-activated receptor-γ agonist pioglitazone suppresses experimental autoimmune uveitis,” Experimental Eye Research, vol. 116, pp. 291–297, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. C. Ulivieri and C. T. Baldari, “The potential of peroxisome proliferator-activated receptor γ (PPARγ) ligands in the treatment of hematological malignancies,” Mini-Reviews in Medicinal Chemistry, vol. 7, no. 9, pp. 877–887, 2007. View at Publisher · View at Google Scholar · View at Scopus
  123. T. Wang, J. Xu, X. Yu, R. Yang, and Z. C. Han, “Peroxisome proliferator-activated receptor gamma in malignant diseases,” Critical Reviews in Oncology/Hematology, vol. 58, no. 1, pp. 1–14, 2006. View at Google Scholar
  124. L. Gelman, J. N. Feige, and B. Desvergne, “Molecular basis of selective PPARγ modulation for the treatment of Type 2 diabetes,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1094–1107, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy-Δ12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ,” Cell, vol. 83, no. 5, pp. 803–812, 1995. View at Publisher · View at Google Scholar · View at Scopus
  126. F. J. Schopfer, Y. Lin, P. R. S. Baker et al., “Nitrolinoleic acid: An endogenous peroxisome proliferator-activated receptor gamma ligand,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 7, pp. 2340–2345, 2005. View at Publisher · View at Google Scholar · View at Scopus
  127. B. Zingarelli and J. A. Cook, “Peroxisome proliferator-activated receptor-γ is a new therapeutic target in sepsis and inflammation,” Shock, vol. 23, no. 5, pp. 393–399, 2005. View at Publisher · View at Google Scholar · View at Scopus
  128. B. Staels and J.-C. Fruchart, “Therapeutic roles of peroxisome proliferator-activated receptor agonists,” Diabetes, vol. 54, no. 8, pp. 2460–2470, 2005. View at Publisher · View at Google Scholar · View at Scopus
  129. C. Zang, H. Liu, M. Waechter et al., “Dual PPARα/γ ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines,” Cell Cycle, vol. 5, no. 19, pp. 2237–2243, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. T. Shibata, K. Matsui, K. Nagao, H. Shinkai, F. Yonemori, and K. Wakitani, “Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative,” European Journal of Pharmacology, vol. 364, no. 2-3, pp. 211–219, 1999. View at Publisher · View at Google Scholar · View at Scopus
  131. Y. Wang, W. W. Porter, N. Suh et al., “A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma,” Molecular Endocrinology, vol. 14, no. 10, pp. 1550–1556, 2000. View at Google Scholar · View at Scopus
  132. P. W. Young, D. R. Buckle, B. C. C. Cantello et al., “Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ,” Journal of Pharmacology and Experimental Therapeutics, vol. 284, no. 2, pp. 751–759, 1998. View at Google Scholar · View at Scopus
  133. Y. Rival, A. Stennevin, L. Puech et al., “Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor γ ligands,” Journal of Pharmacology and Experimental Therapeutics, vol. 311, no. 2, pp. 467–475, 2004. View at Publisher · View at Google Scholar · View at Scopus
  134. C. Rousseaux, B. Lefebvre, L. Dubuquoy et al., “Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma,” The Journal of Experimental Medicine, vol. 201, no. 8, pp. 1205–1215, 2005. View at Publisher · View at Google Scholar · View at Scopus
  135. P. Misra, R. Chakrabarti, R. K. Vikramadithyan et al., “PAT5A: a partial agonist of peroxisome proliferator-activated receptor γ is a potent antidiabetic thiazolidinedione yet weakly adipogenic,” Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 2, pp. 763–771, 2003. View at Publisher · View at Google Scholar · View at Scopus
  136. J. Sakamoto, H. Kimura, S. Moriyama et al., “A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes,” European Journal of Pharmacology, vol. 495, no. 1, pp. 17–26, 2004. View at Publisher · View at Google Scholar · View at Scopus
  137. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000. View at Publisher · View at Google Scholar · View at Scopus
  138. M.-B. Debril, J.-P. Renaud, L. Fajas, and J. Auwerx, “The pleiotropic functions of peroxisome proliferator-activated receptor γ,” Journal of Molecular Medicine, vol. 79, no. 1, pp. 30–47, 2001. View at Publisher · View at Google Scholar · View at Scopus
  139. K. L. Houseknecht, B. M. Cole, and P. J. Steele, “Peroxisome proliferator-activated receptor gamma (PPARγ) and its ligands: a review,” Domestic Animal Endocrinology, vol. 22, no. 1, pp. 1–23, 2002. View at Publisher · View at Google Scholar · View at Scopus
  140. Y.-C. Li, Q. Chen, X.-Z. Wan, X.-L. Yang, X. Liu, and L. Zhong, “Effects of conjugated linoleic acid on cleavage of amyloid precursor protein via PPARgamma,” Neurological Sciences, vol. 32, no. 6, pp. 1095–1101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  141. A. Elbrecht, Y. Chen, A. Adams et al., “L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding,” The Journal of Biological Chemistry, vol. 274, no. 12, pp. 7913–7922, 1999. View at Publisher · View at Google Scholar · View at Scopus
  142. M. P. Pereira, O. Hurtado, A. Cárdenas et al., “The nonthiazolidinedione PPARγ agonist L-796,449 is neuroprotective in experimental stroke,” Journal of Neuropathology and Experimental Neurology, vol. 64, no. 9, pp. 797–805, 2005. View at Publisher · View at Google Scholar · View at Scopus
  143. S. K. Engle, P. F. Solter, K. M. Credille et al., “Detection of left ventricular hypertrophy in rats administered a peroxisome proliferator-activated receptor alpha/gamma dual agonist using natriuretic peptides and imaging,” Toxicological Sciences, vol. 114, no. 2, pp. 183–192, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. S. H. Zuckerman, R. F. Kauffman, and G. F. Evans, “Peroxisome proliferator-activated receptor α,γ coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice,” Lipids, vol. 37, no. 5, pp. 487–494, 2002. View at Publisher · View at Google Scholar · View at Scopus
  145. K. Murakami, K. Tobe, T. Ide et al., “A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ. Effect of PPAR-α activation on abnormal lipid metabolism in liver of Zucker fatty rats,” Diabetes, vol. 47, no. 12, pp. 1841–1847, 1998. View at Publisher · View at Google Scholar · View at Scopus
  146. C. L. Richard and J. Blay, “Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor γ-dependent manner,” International Journal of Oncology, vol. 30, no. 5, pp. 1215–1222, 2007. View at Google Scholar · View at Scopus
  147. S.-H. Sheu, T. Kaya, D. J. Waxman, and S. Vajda, “Exploring the binding site structure of the PPARγ ligand-binding domain by computational solvent mapping,” Biochemistry, vol. 44, no. 4, pp. 1193–1209, 2005. View at Publisher · View at Google Scholar · View at Scopus
  148. J. Kaur and S. N. Sanyal, “Modulation of inflammatory changes in early stages of colon cancer through activation of PPARgamma by diclofenac,” European Journal of Cancer Prevention, vol. 19, no. 5, pp. 319–327, 2010. View at Publisher · View at Google Scholar · View at Scopus
  149. M. A. Lea, M. Sura, and C. Desbordes, “Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists,” Anticancer Research, vol. 24, no. 5, pp. 2765–2771, 2004. View at Google Scholar · View at Scopus
  150. F. M. C. da Silva, J. C. dos Santos, J. L. O. Campos et al., “Structure-based identification of novel PPAR gamma ligands,” Bioorganic and Medicinal Chemistry Letters, vol. 23, no. 21, pp. 5795–5802, 2013. View at Publisher · View at Google Scholar · View at Scopus